[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"motor-function\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:motor-function":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,62,94,136,162,192],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":41,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":61},"100636162","develop-and-evaluate-an-artificial-intelligence-assisted-prehabilitation-program-for-returning-to-work-and-cost-effectiveness-analysis-in-patients-with-oral-cancer-100636162",false,"NCT07562100","Develop and Evaluate An Artificial Intelligence Assisted Prehabilitation Program for Returning to Work and Cost-effectiveness Analysis in Patients With Oral Cancer","Inclusion Criteria:\n\n* Adult (\\> 20 years old and younger than 70 years old)\n* Newly diagnosed as OC and scheduled to receive cancer-related treatment\n* Able to use Mobile phone\n* Willing to sign an informed consent form after receiving a detailed explanation of the study's aims and procedures\n* Healthcare professionals involved in patients' care, including doctors, nurses, case managers, dietitians, rehabilitation therapists, and psychologists\n* Family members who are primary caregivers of the participating patients, engaged in different stages of medical care\n\nExclusion Criteria:\n\n* Risk populations for walking or performing exercise\n* Patients with cognitive impairment or psychiatric diseases",true,"ALL","20 Years","70 Years",{"count":20,"type":21},650,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to develop and evaluate an Artificial Intelligence Assisted Prehabilitation Program (AI APP) for returning to work and cost-effectiveness analysis in patients with oral cancer (OC). The main questions it aims to answer are:\n\n* What kinds of needs are related to returning to work (RTW) in patients with OC from diagnosis to survival that we can incorporate into the development of AI APP to assist this population ?\n* How is the effect of the AI APP that based on findings from the first question for patients with OC on physical and psychological distress, fear of recurrence, self-efficacy in coping with cancer, communication, motor function, quality of life, and RTW?\n* How is the effect of the RTW AI prediction model to identify high-risk groups ? And how is the comprehensive cost effectiveness of benefits and quality of life of the AI APP for OC population?\n\nResearchers will compare patients without using AI APP to see if the AI APP works to assist with coping physical and psychological distress, communication, motor function, quality of life, and RTW issues for individuals with OC?\n\nParticipants will:\n\n* Be asked to fulfill a structural questionnaire, or engage in a semi-structured one-by-one interview or a focus group to assess their physical, psychological, and social support needs in the first stage.\n* Be invited to participant the pilot testing of AI APP in the second stage.\n* Be provided and trained by 3-month AI APP for 3 months or cared as usual in the third stage.\n* Complete a structural questionnaire and follow up one year, including the baseline (before using the AI app) and at 1-2 weeks, 3 months, 6 months, 9 months, and 12 months after the baseline.\n* Engage in one-by-one interview or a focus group to assess user experiences of the AI APP.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Oral Cancer","Psychological Distress","Communication Aids for Disabled","Physiotherapy","Return to Work","Prehabilitation","Physical Symptom Distress","Motor Function","Rehabilitation","Quality of Life","Cost Effectiveness","Artifical Intelligence","Prediction Model","Case Management, APP(Application)",[42,31,27,28,29,30,32,43,44,35,45,46,47,48],"Artificial Intelligence","Physical symptom distress","motor function","Quality of life","Cost effectiveness","prediction model","case management, APP(Application)","RECRUITING","2026-04-24",{"date":52,"type":53},"2026-05-01","ACTUAL",{"date":55,"type":53},"2024-09-27",{"date":57,"type":21},"2029-12-01",{"name":59,"class":60},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",5,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":15,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100631924","feasibility-study-of-the-flash-sole-a-wearable-midsole-with-soft-actuators-for-walking-assistance-100631924","NCT07507006","Feasibility Study of the Flash-Sole: A Wearable Midsole With Soft Actuators for Walking Assistance","Feasibility of Flash-Sole in Human Trials: An Active Midsole Powered by Stacked Dielectric Elastomer Actuators for Push-Off Assistance","Flash-Sole","Inclusion Criteria:\n\n1. Age: 19 to 45 years old at the time of consent\n2. Able to understand study procedures and provide informed consent\n3. Able to walk independently without assistive devices\n4. Willing to wear the Flash-Sole device and complete gait trials during a single session\n5. Body weight under 80 kg to comply with device safety specifications\n\nExclusion Criteria:\n\n1. Current or recent (within 6 months) lower-limb injury, surgery, or fracture\n2. History of neurologic, musculoskeletal, or cardiovascular conditions affecting gait\n3. Skin conditions, open wounds, or known allergies at the foot\u002Fankle that interfere with device wear\n4. Use of implanted electronic medical devices (e.g., pacemakers, neurostimulators)\n5. Cognitive or language impairments that preclude informed consent or task participation\n6. no medication related to musculoskeletal condition (e.g., pain relief medications or similar treatments) .","19 Years","45 Years",{"count":73,"type":21},10,[24],"The goal of this clinical trial is to test a new shoe device called Flash-Sole. The Flash-Sole is designed to help support the ankle while walking. It was developed by researchers at the University of Nebraska at Omaha. The device uses soft materials and electrical signals to gently assist with foot movement.\n\nThe main questions this study aims to answer are:\n\n* Is the Flash-Sole safe to wear?\n* Is it comfortable for users?\n* Does it work as intended to assist walking? This study will include up to 15 healthy adults between the ages of 19 and 45. The Flash-Sole is considered investigational and is not approved by the U.S. Food and Drug Administration (FDA).\n\nParticipants will:\n\n* Complete one visit at the Biomechanics Research Building that lasts about 2 hours\n* Answer a few health questions to make sure they can join the study\n* Do short walking trials wearing their own shoes\n* Wear special shoes with the Flash-Sole device\n* Walk short distances on a treadmill at a comfortable speed while the device is turned on and off\n* Wear small, sticky sensors on their legs to measure movement and muscle activity\n* Wear a safety harness to prevent falls\n* Complete a short survey about how the shoes felt and how easy they were to use The purpose of this early study is to learn how the device performs and how people feel about wearing it. The results may help guide improvements to the device and inform future studies. This research is not testing whether the device helps people with walking problems yet, but it may lead to that kind of research in the future.",[34],[78,79,80,81],"Assistive Walking Device","Robotic Footwear","Gait Support","Wearable Technology","NOT_YET_RECRUITING","2026-03-26",{"date":85,"type":53},"2026-04-02",{"date":87,"type":21},"2026-07-15",{"date":89,"type":21},"2026-09-30",{"name":91,"class":92},"University of Nebraska","OTHER",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100391175","phase-4-effect-on-body-movement-and-mental-skills-in-patients-who-received-gadolinium-based-contrast-media-for-magnetic-resonance-examination-multiple-times-within-5-years-100391175","NCT04373564","Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years","Prospective Evaluation of Potential Effects of Repeated Gadolinium-based Contrast Agent (GBCA) Administrations of the Same GBCA on Motor and Cognitive Functions in Neurologically Normal Adults in Comparison to a Non-GBCA Exposed Control Group","ODYSSEY","Inclusion Criteria:\n\n* Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening\n* Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years)\n* Participants should have at least 1 of the following indications: a) Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI, b) Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer, c) Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development, d) Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver metastases or e) Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance.\n\nIn addition, for participants in the GBCA Arms only:\n\n* Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration\n* Prospective participants with up to 3 well documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he\u002Fshe cannot be enrolled.\n\nFor the Control Arm:\n\n* Participants who never had and are not likely to receive any GBCA injection during the course of the study\n* Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures\n\nExclusion Criteria:\n\n* As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and\u002For psychiatric disease (or treatments) that could influence the results of the study's motor and cognitive tests (e.g. Cerebrovascular disease, Multiple sclerosis, Neurodegenerative disease, Malignant disease other than listed in indications, Carcinoid tumors, Epilepsy, Prior neurosurgery, Psychotic disorders or any prior psychotic episode not otherwise specified - any documented prior history of chronic schizophrenia, Remittent or current medically confirmed major depressive disorder or bipolar disorder, History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years, Neurodevelopmental disorders (eg, trisomy 21), Uncontrolled severe migraine, Uncontrolled or controlled anxiety or depression within 6 months before enrollment, Screening scores of ≤24 on the MMSE and\u002For ≥11 on the Hospital Anxiety and Depression Scale (HADS)).\n* Prior, planned, or ongoing chemotherapy or brain irradiation\n* Use of concomitant medication(s) affecting neuro-cognitive or motor function\n* Substance or alcohol abuse as determined by the investigator\n* Alcoholic cirrhosis\n* Renal disease, defined as estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m2\n* History of environmental\u002Foccupational\u002Fother exposure to one or more chemicals that may affect cognitive and\u002For motor function, including, but not limited to, heavy metals (arsenic \\[As\\], cadmium \\[Cd\\], lead \\[Pb\\], manganese \\[Mn\\], and mercury \\[Hg\\]), pesticides, solvents, or carbon monoxide.\n* Clinical indications requiring \\>1 contrast enhanced magnetic resonance imaging (CE-MRI) every 6 months\n* Pregnant or nursing (lactating) women\n* Presence of any metal-containing joint implants\u002Fprostheses\n\nIn addition, for participants in either of the GBCA Arms only:\n\n\\- Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study.\n\nFor participants in the Control Arm only:\n\n* Participants with any previous exposure to a GBCA.\n* Participants with any contraindication to UE-MRI examinations.","18 Years","64 Years",{"count":105,"type":21},2076,[107],"PHASE4","This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.\n\nThe study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth.\n\nIn this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years.\n\nThe study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.",[34,110,111],"Cognitive Function","Contrast Media",[113,114,115,116,117,118,119,120,121,122,123,124],"Motor function assessment","Cognitive function assessment","Magnetic Resonance Imaging (MRI)","Gadolinium","Gadolinium-based contrast agent (GBCA)","Gadolinium retention","Breast cancer","Prostate cancer","Hepatocellular carcinoma","Colorectal cancer","Neuroendocrine tumor","Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas","2026-01-21",{"date":127,"type":53},"2026-01-22",{"date":129,"type":53},"2021-03-24",{"date":131,"type":21},"2028-12-31",{"name":133,"class":134},"Guerbet","INDUSTRY",51,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":93},"100585423","effect-of-diving-and-aquatic-exercises-on-muscle-spasticity-and-motor-function-in-children-with-spastic-cerebral-palsy-100585423","NCT06902168","Effect of Diving and Aquatic Exercises on Muscle Spasticity and Motor Function in Children With Spastic Cerebral Palsy","Inclusion Criteria:\n\n* Age from 2 to 5 years.\n* Both sexes.\n* Children diagnosed with spastic cerebral palsy, categorized according to the Gross motor function classification system (GMFCS) levels IV, V.\n\nExclusion Criteria:\n\n* Botulinum toxin treatment or surgery in the preceding three months.\n* Botox injections before or during the application of the program.\n* Dorsal rhizotomy.","2 Years","5 Years",{"count":145,"type":21},37,[24],"This study aims to evaluate the effect of diving and aquatic exercises on muscle spasticity and motor function in children with spastic cerebral palsy.",[149,150,151,34,152,153],"Diving","Aquatic","Muscle Spasticity","Children","Spastic Cerebral Palsy","2025-03-29",{"date":156,"type":53},"2025-04-01",{"date":154,"type":53},{"date":159,"type":21},"2025-08-01",{"name":161,"class":92},"Benha University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100584686","rehabilitation-paired-with-vns-for-motor-function-recovery-100584686","NCT06892574","Rehabilitation Paired with VNS for Motor Function Recovery","A Trial of Rehabilitation Paired with VNS for Motor Function Recovery in Post-ICH Patients (Recovery Study)","Inclusion Criteria:\n\n* Age ≥22 years and \\\u003C80 years, all gender is acceptable.\n* History of unilateral supratentorial intracerebral hemorrhage ≥ 6 months but \\\u003C 5 years.\n* Upper Extremity motor section of the Fugl-Meyer Assessment score ≥20 and ≤50.\n* Right- or left-sided weakness of upper extremity.\n* Ability to communicate, understand, and give appropriate consent. Subjects can follow trial commands.\n* Subjects have good compliance and can complete the visits after surgery.\n\nExclusion Criteria:\n\n* History of ischemic stroke.\n* Cerebral hemorrhage resulting from tumors, trauma, aneurysms, or hemorrhagic transformation of ischemic stroke.\n* Presence of ongoing dysphagia or aspiration difficulties.\n* Prior injury to vagus nerve, either bilateral or unilateral.\n* Subject receiving medication that may significantly interfere with actions of VNS on neurotransmitter systems at study entry, clinic rehabilitation follow-up timepoint, or home rehabilitation follow-up timepoint, such as centrally acting cholinoceptor blockers, centrally acting adrenoceptor blockers, norepinephrine re-uptake inhibitors, etc.\n* Botox injections within 4 weeks prior to enrollment through the unmasking follow-up timepoint (Visit 6).\n* Severe spasticity of the upper extremity (Modified Ashworth ≥ 3).\n* Significant sensory loss of the upper extremity (Upper Extremity sensory section of the Fugl-Meyer Assessment score \\\u003C 6).\n* Current requirement, or likely future requirement, of diathermy.\n* Current use of any other stimulation device, such as a pacemaker or other neurostimulator.\n* Pregnancy or plans to become pregnant or to breastfeed during the study period.\n* Participated in any other clinical trials within the preceding 3 months.\n* Not considered to be applicable by the investigator.","22 Years","79 Years",{"count":73,"type":21},[24],"The goal of this clinical trial is to investigate the efficacy and safety of vagus nerve stimulation (VNS) combined with rehabilitation in improving upper extremity motor function after spontaneous intracerebral hemorrhage (ICH).\n\nResearchers will evaluate the efficacy and safety of VNS by comparing the improvements of arm motor function post-ICH in the active VNS combined rehabilitation group with that in the sham VNS combined rehabilitation group (actual intensity 0 mA).\n\nParticipants in this study will undergo a surgical procedure to implant the VNS system and will subsequently recieve a 6 weeks in-clinic therapy, followed by an additional 6 weeks home exercise. During the final 6 weeks, participants will either recieve in-clinic therapy or maintain their home exercise, depending on their assigned group.",[175,34,176,35,177],"Spontaneous Intracerebral Hemorrhage","Upper Extremity Injury","Vagus Nerve Stimulation",[179,180,181,177,182,183,35],"Stroke","Hemorrhagic Stroke","Upper Extremity Paresis","Neuromodulation","Randomized Controlled Trial","2025-03-23",{"date":186,"type":53},"2025-03-26",{"date":156,"type":21},{"date":189,"type":21},"2027-12-30",{"name":191,"class":92},"First Affiliated Hospital of Fujian Medical University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":199,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":93},"100551835","effects-of-home-based-cimt-and-clinic-based-cim-on-stroke-100551835","NCT06465251","Effects of Home-based CIMT and Clinic-based CIM on Stroke","Effects of Repetition Home-based Constraint Induced Movement Therapy (CIMT) Compared With Repetition Clinic-based CIMT on Outcomes Post Stroke: A Randomized Controlled Trial","Inclusion Criteria:\n\n* have stroke 1-2 years before\n* moderate disability\n* a score of 1 to 3 on the motor arm item of the National Institutes of Health Stroke Scale (NIHSS)\n* a score of 3 or more on the upper arm item of the Motor Assessment Scale (MAS)\n* no significant cognitive impairment (a score of ≥24 points on Minimental state examination)\n\nExclusion Criteria:\n\n* patients with re-stroke\n* serious orthopaedic conditions such joint contracture, osteoarthritis and burns that will interfere with carrying out CIMT\n* who are receiving rehabilitation at the time of the study","50 Years",{"count":201,"type":21},96,[24],"Constraint induced movement therapy (CIMT) is based on the theoretical basis that constraining the unaffected limb following injury of the brain such as stroke can help overcome learned non-use. It comprises of constraint of the unaffected limb, massed tasks practice with the affected limb and a behavioral contract known as the transfer package whereby use of the affected limb is extended to the real-world situations. home-based rehabilitation is likely to be cost-effective, and it may reduce cost for patients in terms of hospital charges and transport fares. However, one of the major problems with the existing home-based CIMT protocols is that, they used number of hours spent carrying out tasks practice as the measure of intensity of practice, and it has been argued that, such method is not clear and it does not reflect the correct intensity of practice.",[34],[206,207],"Constraint Induced Movement Therapy","Disability","2024-06-13",{"date":210,"type":53},"2024-06-18",{"date":212,"type":53},"2024-03-01",{"date":214,"type":21},"2024-12-01",{"name":216,"class":92},"The Hong Kong Polytechnic University"]